Bladder cancer (BCa) is burdened by high rates of chemo-and radio-resistance. We
reviewed and summarized the current evidence regarding the genetic determinants of …

Metastatic disease is the most common mechanism of death in patients with advanced
bladder cancer. As for most solid tumors, chemotherapy remains the only realistic option for …

Aims: Platinum-based chemoradiotherapy (CRT) as bladder conservation therapy has
shown promising results for muscle-invasive bladder cancer. However, treatment-related …

The combination chemotherapies with methotrexate plus vinblastine, doxorubicin and
cisplatin (MVAC or CMV regimens) or gemcitabine plus cisplatin represent the standard as …

Chemotherapy resistance is an obstacle to cancer therapy and is considered a major cause
of recurrence. Thus, understanding the mechanisms of chemoresistance is critical to …

The 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium (MTT) test was employed as a
means of studying the cross resistance and collateral sensitivities of two bladder cell lines …

BACKGROUND The authors characterized the genetic landscape of chemoradiation‐treated
urothelial carcinoma of the bladder (UCB) with the objective of identifying potential …

Bladder cancer is one of the most common malignancies in the world. Cisplatin is one of the
most potent and widely used anticancer drugs and has been employed in several …

Bladder cancer stands as a prevalent global malignancy, exhibiting notable sex-based
variations in both incidence and prognosis. Despite substantial strides in therapeutic …

Cancer is a leading cause of death worldwide. Surgery is the primary treatment approach for
cancer, but the survival rate is very low due to the rapid progression of the disease and …